Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析

◆英語タイトル:Dicerna Pharmaceuticals Inc (DRNA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH93530FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥79,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥119,700見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dicerna Pharmaceuticals Inc (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver such as rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Cambridge, Massachusetts, the US.

Dicerna Pharmaceuticals Inc Key Recent Developments

Apr 01,2021: Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 30,2021: Dicerna’s GalXC-Plus RNAi Technology delivers target knockdown across CNS and to specific CNS cell types in preclinical studies
Mar 24,2021: Dicerna to present new GalXC-Plus nonclinical CNS data at Oligonucleotide and Precision Therapeutics Virtual Congress
Mar 05,2021: Dicerna and Roche commence Hepatitis B virus therapeutic trial

This comprehensive SWOT profile of Dicerna Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Dicerna Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Dicerna Pharmaceuticals Inc – Key Information
Dicerna Pharmaceuticals Inc – Overview
Dicerna Pharmaceuticals Inc – Key Employees
Dicerna Pharmaceuticals Inc – Key Employee Biographies
Dicerna Pharmaceuticals Inc – Key Operational Heads
Dicerna Pharmaceuticals Inc – Major Products and Services
Dicerna Pharmaceuticals Inc – History
Dicerna Pharmaceuticals Inc – Company Statement
Dicerna Pharmaceuticals Inc – Locations And Subsidiaries
Dicerna Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Dicerna Pharmaceuticals Inc – Business Description
Dicerna Pharmaceuticals Inc – Corporate Strategy
Dicerna Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Dicerna Pharmaceuticals Inc – Strengths
Dicerna Pharmaceuticals Inc – Weaknesses
Dicerna Pharmaceuticals Inc – Opportunities
Dicerna Pharmaceuticals Inc – Threats
Dicerna Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Dicerna Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Dicerna Pharmaceuticals Inc, Key Information
Dicerna Pharmaceuticals Inc, Key Ratios
Dicerna Pharmaceuticals Inc, Share Data
Dicerna Pharmaceuticals Inc, Major Products and Services
Dicerna Pharmaceuticals Inc, History
Dicerna Pharmaceuticals Inc, Key Employees
Dicerna Pharmaceuticals Inc, Key Employee Biographies
Dicerna Pharmaceuticals Inc, Key Operational Heads
Dicerna Pharmaceuticals Inc, Other Locations
Dicerna Pharmaceuticals Inc, Subsidiaries
Dicerna Pharmaceuticals Inc, Key Competitors
Dicerna Pharmaceuticals Inc, SWOT Analysis
Dicerna Pharmaceuticals Inc, Ratios based on current share price
Dicerna Pharmaceuticals Inc, Annual Ratios
Dicerna Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Dicerna Pharmaceuticals Inc (DRNA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Elders Limited:企業のM&A・事業提携・投資動向
    Elders Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Elders Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Jones Packaging Inc.:企業の戦略的SWOT分析
    Jones Packaging Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Nektar Therapeutics (NKTR):企業の財務・戦略的SWOT分析
    Nektar Therapeutics (NKTR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Innovation Pharmaceuticals Inc (IPIX)-製薬・医療分野:企業M&A・提携分析
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp is a biopharmaceutical company that offers discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company offers kevetrin for t …
  • Exillon Energy Plc (EXI):石油・ガス:M&Aディール及び事業提携情報
    Summary Exillon Energy Plc (Exillon) is an oil exploration and production company. The company explores, produces and develops crude oil. Its services include drilling, exploration, appraisal, development, operations, management, and production services. Exillon’s operating assets are located in two …
  • Murray & Roberts Holdings Ltd (MUR):企業の財務・戦略的SWOT分析
    Murray & Roberts Holdings Ltd (MUR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • The British United Provident Association Limited :企業の戦略・SWOT・財務情報
    The British United Provident Association Limited - Strategy, SWOT and Corporate Finance Report Summary The British United Provident Association Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • Green Earth Technologies Inc (GETG):企業の財務・戦略的SWOT分析
    Summary Green Earth Technologies Inc (GET) is a clean technology company that develops and markets of bio-based performance and cleaning products. The company’s products include small engine oils, motor oils, lubrication and engine protection oils. It also provides wheel cleaner, hydrophobic car was …
  • BoneSupport AB:企業の製品パイプライン分析2018
    Summary BoneSupport AB (BoneSupport), a subsidiary of Bonesupport Holding AB, is a orthobiologics company that develops, manufactures and markets injectable bioceramic bone graft substitutes for the treatment of fragility fractures caused by osteoporosis; bone voids and gaps caused by trauma; infect …
  • Diebold Nixdorf, Incorporated:戦略・SWOT・企業財務分析
    Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Diebold Nixdorf, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Onconova Therapeutics Inc (ONTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Onconova Therapeutics Inc (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib, briciclib and recilisib. It develops drug candidates that target cancer and protect he …
  • Community Health Systems Inc (CYH):企業の財務・戦略的SWOT分析
    Community Health Systems Inc (CYH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • EnGeneIC Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary EnGeneIC Ltd (EnGeneIC) is a biopharmaceutical company that develops drugs and other therapeutic molecules. The company develops nanocell platform used as a platform for the creation of custom therapies for cancer. Its cyto-immunotherapy platform releases concentrations of RNA-interference m …
  • Pliant Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pliant Therapeutics Inc (Pliant Therapeutics) is a biotechnology company that strives to discover, develop and commercialize treatments for fibrotic diseases. The company harnesses its capabilities in integrin biology, medicinal chemistry, clinical insight and TGF-ß modulation to block or re …
  • 908 Devices Inc:医療機器:M&Aディール及び事業提携情報
    Summary 908 Devices Inc (908 Devices) is a manufacturer of handheld chemical detection tools, tiny footprint analyzers and fast separation devices. The company’s product portfolio includes MX908, a second-generation tool that leverages high-pressure mass spectrometry (HPMS); M908 focuses on priority …
  • Cohort Plc
    Cohort Plc - Strategy, SWOT and Corporate Finance Report Summary Cohort Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Covance Inc:医療機器:M&Aディール及び事業提携情報
    Summary Covance Inc (Covance), a subsidiary of LabCorp, is a drug development company that offers contract research and manufacturing services. The company offers a broad range of early-stage and late-stage product development services to pharmaceutical, biotechnology and medical device companies. I …
  • China Petrochemical Corp:企業のM&A・事業提携・投資動向
    China Petrochemical Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Petrochemical Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisiti …
  • Fomento de Construcciones y Contratas SA (FCC)-エネルギー分野:企業M&A・提携分析
    Summary Fomento de Construcciones y Contratas SA (FCC) is a citizen services company. It manages and treats domestic and industrial waste; provides integrated water management services; and designs, develops and maintains infrastructure. The company provides engineering and construction services for …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆